Delta 9 Cannabis Inc. (CVE:NINE) (OTCMKTS:VRNDF) (FRA:V5D1) is one of the first Health Canada licensed producers and distributors of medical cannabis products. CEO John Arbuthnot talks about their production facility in Manitoba, as well as their unique growing method in retrofitted shipping containers.
James West: John, thanks for joining us today.
John Arbuthnot: Thank you for having me.
James West: John, let’s start with an overview: what does Delta 9 do, and what differentiates it from others in its sector?
John Arbuthnot: Well, we are Delta 9 Cannabis. We’re a Health Canada licensed producer/distributor of medical cannabis products currently. We’ve been licensed under Canada’s MMPR and ACMPR programs since 2013, so we are one of the earlier licensed producers…
James West: You were the fourth, if I’m not mistaken.
John Arbuthnot: The fourth, yeah. We’ve been through the Health Canada system for quite some time now.
James West: Well, that’s great. Okay, and so what does Delta 9 – is it a greenhouse operation, indoor operation?
John Arbuthnot: We currently operate out of an 80,000 square foot production facility here in Winnipeg, Manitoba. We are entirely indoor or warehouse, and a little bit unique in terms of our production style. We are entirely hydroponic in terms of our actual output production, so we essentially remove the soil medium, deliver the plant nutrients right to the rooting system. If we do it right, we’re able to achieve accelerated growth rates and an increased yield.
As well as our facility design is very unique. We grow in what we call Delta 9 grow pods, which are effectively retrofitted shipping containers. We take a standard, 40-foot-high shipping container, install our own customized wall panels, coat the entire interior with epoxy, which gives us hospital-grade cleanable surfaces. We then install electrical, lighting and HVAC systems and security, and what we’re left with is a modular, scalable, now stackable unit, which is compliant with all of Health Canada’s ACMPR regulations.
James West: Interesting! Okay, so what is the nature of your patient base? Are you focused on any particular segment, or is your audience sort of across Canada, or are they Manitoba-centric?
John Arbuthnot: We’re currently distributing to about 2,200 patients across Canada. Now, about half of those are located here in our home province of Manitoba, so we are very focused on our home province here. In terms of market share in our own backyard, we have about 33 percent of the overall patient base here in Manitoba; actually, a little bit upwards of that. So we are big fish in our own pond, here.
James West: Sure, okay. How many patients is that, roughly?
John Arbuthnot: About 1,100 patients here locally.
James West: Okay, great. So you took, you got your license initially in 2013, but it’s taken you till November of this year to become a publicly traded company. Why did you wait so long?
John Arbuthnot: Well, you know, we walked through, I want to say the growing pains of the sector, the learning curve, as it were. We have, over the last three years, completely changed our room design from our original rather rudimentary room style